ALDX Investors Have Opportunity to Lead Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

robot
Abstract generation in progress

The Schall Law Firm is notifying investors of a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) for alleged securities fraud. The lawsuit claims that Aldeyra made false and misleading statements regarding inconsistent clinical trial results for its reproxalap drug candidate. Investors who purchased securities between November 3, 2023, and March 16, 2026, are encouraged to contact the firm by May 29, 2026, to potentially lead the lawsuit.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin